1. Home
  2. BOLD
  3. BOLD News

Latest Boundless Bio Inc. Common Stock (BOLD) News on November 24, 2024

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
BOLD

GlobeNewswire

17 days ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
BOLD

GlobeNewswire

19 days ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Boundless Bio Announces Departure of Chief Financial Officer
BOLD

GlobeNewswire

a month ago

Boundless Bio Announces Departure of Chief Financial Officer

Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?
BOLD

Simply Wall St.

2 months ago

Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
BOLD

GlobeNewswire

2 months ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now?
BOLD

Insider Monkey

3 months ago

Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now?

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
BOLD

GlobeNewswire

3 months ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BOLD

Business Wire

6 months ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
BOLD

Business Wire

6 months ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
BOLD

Business Wire

7 months ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
BOLD

Business Wire

7 months ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
BOLD

Business Wire

8 months ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Share on Social Networks: